In a report released today, Ami Fadia from Needham maintained a Buy rating on GH Research, with a price target of $19.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ami Fadia’s rating is based on several key factors. Firstly, GH Research’s financial performance in the third quarter of 2025 was largely in line with expectations, with an EPS of -$0.23 compared to the consensus of -$0.24. This stability in earnings, despite ongoing challenges, suggests a solid financial foundation. Additionally, the company is actively engaging with the FDA to address the IND hold, which indicates a proactive approach to regulatory hurdles.
Moreover, the recent data presented at the ECNP Congress 2025 highlighted the safety profile of GH-001, a promising psychedelic treatment for treatment-resistant depression (TRD). Although there were some adverse events reported, the overall safety profile remains compelling. With a substantial cash reserve of $293.9 million as of September 30, 2025, GH Research is well-positioned to advance its pivotal program in 2026. These factors collectively support the Buy rating as the company continues to address regulatory challenges and progress in its clinical development.
Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Revolution Medicines. According to TipRanks, Fadia has an average return of 19.4% and a 51.80% success rate on recommended stocks.